Navigation Links
NxStage to Report Fourth Quarter and Full Year 2008 Financial Results
Date:2/3/2009

LAWRENCE, Mass., Feb. 3 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2008 on Thursday, March 12, 2009 before the opening of the financial markets.

NxStage will also host a conference call at 9:00 a.m. Eastern Time on Thursday, March 12, 2009 to discuss its fourth quarter and year end 2008 financial results. To listen to the conference call, please dial 800-510-0178 (domestic) or 617-614-3450 (international). The passcode is 90754499. The call will also be webcast LIVE and can be accessed via the investor relations section of the Company's website at www.nxstage.com/ir.cfm.

A replay of the conference call will be available 3 hours after the start of the call through March 26, 2009. To access the replay dial 888-286-8010 (domestic) or 617-801-6888 (international) and enter passcode 22219789. An online archive of the conference call can be accessed via the investor relations section of the Company's website at www.nxstage.com/ir.cfm.

About NxStage

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the company's website at www.nxstage.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. The forward-looking statements in this release include NxStage's plan to release its financial results on March 12, 2009. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, but not limited to, unexpected difficulty in closing the company's financial books for the quarter and other factors that are discussed in NxStage's Quarterly Report on Form 10-Q for the period ended September 30, 2008 filed with the SEC. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

    Contact: Kristen K. Sheppard, Esq.
    VP, Investor Relations
    ksheppard@nxstage.com


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. First NxStage Home Hemodialysis Patients Celebrate Five-Year Anniversary
2. NxStage(R) Ranked 14th Fastest Growing Company in North America on Deloittes 2008 Technology Fast 500
3. NxStage Applauds Array of Studies To Be Presented at American Society of Nephrology Meeting
4. NxStage(R) Achieves Milestone with 3,000 End-Stage Renal Disease Patients Receiving Daily Home Hemodialysis Therapy
5. NxStage Reports Third Quarter 2008 Financial Results
6. NxStage Appoints New Member to Its Board of Directors and Announces Resignation of Board Member
7. NxStage Announces Presentation of Data at the American Society of Nephrologys Renal Week 2008 Annual Meeting
8. NxStage Reports Second Quarter 2008 Financial Results
9. NxStage Announces $43 Million Private Placement of Equity Securities
10. NxStage Medical Reports First Quarter 2008 Results
11. NxStage Announces Supply Agreement With Kawasumi Laboratories for Blood Tubing Sets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... ... acquired Presence Technology, S.L. (“Presence”) for a purchase price of approximately $17.4 ... other considerations. Presence’s annual revenue is approximately $13.2 million. Headquartered in Barcelona, ...
(Date:12/7/2016)... ... December 07, 2016 , ... Levels of a protein ... according to a study appearing online in the journal Radiology. , Heart disease and ... increase significantly due to the rapidly aging population. Damage to both organs often occurs ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... consultation services to residents in the Sacramento/Folsom region, is initiating a charity event ... , The Another Choice Another Chance treatment center in Sacramento works to provide ...
(Date:12/7/2016)... ... OCTOBER XX, 2016 (PRWEB) (PRWEB) December 07, 2016 , ... ... study entitled “Canine Filamentous Dermatitis Associated with Borrelia Infection” reveals ... study was published in the prestigious Journal of Veterinary Science & Medical Diagnosis. ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... in Dallas, Texas, is condemning "scam operations" carried out by unethical locksmith companies ... these scam operations to a halt. According to Texas Premier Locksmith, these fraudulent ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... , December 7, 2016 ... Market Research titled , Global Market Study on Multiplex Detection ... 2024 , the global multiplex detection immunoassay market is expected ... period 2016-2024. ... , , ...
(Date:12/7/2016)... , December 7, 2016 ... reach a value of USD 3.9 billion by ... View Research, Inc. The growth of the market ... and continuous technological advancements by the market players. ... due to increasing donation, rising awareness about transfusion-transmitted ...
(Date:12/6/2016)... , Dec. 6, 2016  Alopexx Oncology, LLC ... a recombinant antibody fusion protein (immunocytokine) composed of interleukin-2 ... the same target on B cells as Rituxan and ... components but is also involved in tumor targeting, engagement ... vaccine effect. The results of the study (abstract #95954) ...
Breaking Medicine Technology: